RESEARCH DOSSIER
Health Insurance Prior Authorization and Medical Necessity Review
Abstract. Prior authorization and medical necessity review determine how health insurance entitlements govern proposed clinical care. This fundamental international research monograph reconstructs the history and institutional logic of prospective utilization management, patient-specific clinical criteria, regulatory review deadlines, appeal procedures, administrative costs, behavioral responses, treatment outcomes, and data requirements for causal policy evaluation. The source base includes United States Medicare Advantage and federal interoperability regulations, government audit and administrative reporting, original physician and stakeholder surveys, a specialty oncology cohort, a systematic drug-authorization cost review, and official European Union, English and Ontario documents. Data reported from Medicare Advantage in 2024 involve about 52.8 million determinations, a 7.7% fully or partly adverse rate, and high appeal-reversal frequencies among a selected subset; each figure has a distinct denominator. Hypothetical workload and appeal calculations demonstrate inference constraints without purporting to estimate actual clinical effects. The work differentiates medical indications from coverage decisions, payer turnaround from order-to-treatment delay, and cross-border exceptional reimbursement from ordinary insurance authorization. It concludes that meaningful performance assessment joins legal entitlement, individualized evidence, transparent decision-making, accessible review and actual service delivery. The original contribution is documentary, comparative and methodological synthesis, without a new doctrine or an unsupported causal estimate.
Keywords: Health insurance; prior authorization; medical necessity review; utilization management; clinical evidence; Medicare Advantage; appeals; review delays; treatment access; administrative burden; health outcomes; fairness; interoperability; clinical appropriateness; international comparative health financing; causal inference.
Introduction: The Scientific Object of Prior Authorization
Prior authorization is a prospective determination of whether a proposed service, treatment course, device, or medication satisfies conditions imposed by a health financing arrangement before its cost will be covered. Medical necessity review is the clinical-evidentiary determination that a specific intervention is justified for a particular patient's circumstances under the applicable coverage criteria. Together they connect financial coverage promises to individual clinical decisions. The meaning of a favorable decision is therefore circumscribed: authorization permits access to a covered payment pathway under stated conditions, while actual treatment, quality, and eventual claims payment depend on further events.
The fundamental research object comprises six observable levels. The clinical level concerns need, diagnosis, alternatives, expected benefit, risk, and urgency. The contractual and statutory level determines entitlement. The administrative level governs evidence submission, review, notification, reconsideration, and appeal. The economic level concerns costs, incentives, and the incidence of burden. The clinical-outcomes level asks what care was delivered and with what consequences. The institutional level encompasses supervision, accountability, transparency, and differences across health systems. These levels are related through patient pathways but require distinct measurements.
An authorization request is not an insured person, a treatment episode, a diagnosis, or a claim. A patient may generate several requests in the same episode; a decision may be partly favorable; a declined request may subsequently be revised; and a provider may choose an alternative before making a request. Request-level approval rates are consequently insufficient to describe patient access. The Medicare Advantage administrative analysis illustrates the scale of requests and the importance of explicitly defining decisions, denials, and appeals.
The monograph integrates primary U.S. Medicare regulation and oversight with carefully delimited European and Canadian institutional comparisons, original observational studies, physician surveys, and published methods. It supplies independently reasoned interpretation of incentives, selection, measurement, and outcomes. The document makes no claim to possess unpublished patient-level data or to establish a newly invented theoretical system. Its quantitative examples are illustrative calculations whose assumptions are shown and whose estimates are not represented as real-world causal effects.
Research questions and methodological commitments
The first question is what constitutes adequate medical necessity evidence within an actual legal entitlement, and who possesses authority to interpret it. The second is how administrative decisions, waiting, and appeals affect access to clinically indicated care. The third is how a research design can identify the financial, clinical, and distributional effects of these mechanisms across jurisdictions with different institutions.
The evidentiary procedure assigns official legal and regulator sources to legal claims; administrative datasets and audits to measurable program events; original clinical studies to the observed patient pathways in their own sampling frames; participant surveys to reported experiences; and comparative official documentation to institutional description. A hypothetical calculation supports arithmetic consequences of explicit assumptions. None of these categories is substituted for another. Jurisdiction, effective date, denominator, clinical case mix, and causal identification strategy are attached to every material conclusion.
Foundations and Source-Critical History
From utilization management to prospective coverage control
As insurers and publicly financed purchasers expanded financing commitments, clinical decisions occurred in settings where clinicians and patients possessed more detailed information about need than the eventual payer. Prospective utilization management became one response to the combination of rising expenditures, heterogeneous clinical practices, and uneven evidence concerning value. A reviewer could in principle prevent a duplicate test, a medically inappropriate admission, or an ineffective medicine. The same intervention could also impose documentation costs, misclassify unusual cases, and delay necessary treatment. Historical development thus requires evaluating both potential risk control and access consequences.
The meaning of authorization follows the nature of the financing system. In a defined-benefit private insurance product the immediate issue may be whether covered criteria for a scheduled procedure are met. In capitated managed care the institution receives population-level revenue while managing downstream covered expenditure. In an NHS exceptional funding process, the intervention may lie outside a routinely commissioned service set. In a provincial drug formulary, the question may be whether a nonlisted medication qualifies for an exceptional reimbursement route. Each setting involves prospective expenditure control but differs in the originating entitlement.
Under Medicare Advantage the CMS 2024 coverage rule supplies detailed restrictions on coverage criteria and utilization management. The NHS individual funding guidance concerns exceptional clinical circumstances for treatments outside routine commissioning. The differences imply that approval rates or turnaround times alone cannot be assembled into a coherent international league table. The unit of entitlement and the baseline funding promise must first be reconstructed.
A conceptual classification of decisions
A benefit-basket determination asks whether a service is ordinarily funded at all. Medical necessity review asks whether covered criteria are satisfied for this patient. Administrative completeness review asks whether the needed documentation was received. A network decision specifies which institution or clinician is eligible to furnish the service. A drug formulary restriction may impose prior approval, quantity limitations, or step therapy. Claims adjudication happens after care and asks whether the submitted bill complies with payment rules. Although operational systems combine these stages, they embody distinct rights, evidence, and appeal routes.
An adverse result can mean complete denial, reduction in approved quantity or duration, authorization of a different service, or a request to submit new evidence. These events should have different reason codes. A partial authorization for three therapy visits when twelve were requested is clinically meaningful even though some care is approved. The CMS-based 2024 determination figures group complete and partial adverse decisions in the reported denial measure. Treating all partial outcomes as approvals would change that statistic and conceal treatment-dose restrictions.
Evidence provenance and historical applicability
Government investigations can reveal failure modes when they examine specific decisions against governing standards. The 2022 inspector general evaluation reviewed a sample of already denied Medicare Advantage prior-authorization cases, focusing on whether Medicare coverage rules were met. It did not sample all treatment orders or all authorization decisions in the country. Its period of observation predates subsequent rule revisions. The resulting evidence is highly relevant to institutional control weaknesses, while its selection frame limits extrapolation.
Professional associations report valuable experience with paperwork and delay. The AMA physician survey provides a 2025 survey released in 2026, and the multi-stakeholder survey captures responses from patients, provider employees, and private payers. These instruments measure reported experiences rather than a common clinical outcome, and their respondents are not independent random draws from the entire insured population. Their strongest role is to identify organizational burdens and hypotheses for testing in patient-level datasets.
The clinical evidence base must similarly retain its source setting. A specialty-center oncology study reflects its specific order types, insurer mix, hospital scheduling, and disease pathways. A review of drug authorization costs combines cost estimates from studies that differ in workflows, wages, and payers. Both help map mechanisms, but neither supplies a universal benchmark for all authorization systems. Reproducible evidence synthesis starts by preserving these distinctions rather than hiding them in a pooled average.
Medical Necessity Criteria and Clinical Evidence
Entitlement, indication, and individualized judgment
A medical necessity finding requires a relationship between a covered service, a clinically meaningful indication, and the particular patient's condition. A general guideline may identify typical patients for whom an intervention is effective. The review must still consider severity, disease stage, coexisting illnesses, prior treatment, contraindications, the suitability of alternatives, and the cost of waiting. A standard becomes clinically fragile when its abstraction excludes the conditions that make an individual case atypical.
The Medicare Advantage final rule distinguishes applicable traditional Medicare coverage criteria from plan-developed internal criteria. Such internal criteria can be used in specified circumstances where Medicare criteria are not fully established, subject to evidentiary and accessibility requirements. The February 2024 CMS memorandum clarifies consideration of individual medical circumstances, medical history, physician recommendations, and clinical notes; predicted outcomes produced by an algorithm do not independently resolve individual clinical necessity. This is a jurisdiction-specific Medicare Advantage rule, not a universal legal standard for private insurance globally.
The reviewer should identify whether a disputed service is an uncovered benefit, a covered benefit with unmet clinical criteria, a covered service with insufficient documentation, or a service eligible under an exception. These are different reasons for nonapproval. If the claim concerns missing documentation, additional clinical information may alter the result without changing the rule. If a clinical criterion is wrong or outdated, a reconsideration requires substantive reassessment of the criterion itself.
Criteria governance and medical knowledge
A scientifically inspectable medical policy states its intervention, target population, indication, comparator, relevant harms, evidence grade, date of literature review, and rule version. It specifies how an individual exception is evaluated, how guideline updates become effective, and whether urgent treatment receives a separate process. Criteria should be written so that the treating clinician can understand which factual element is contested.
A general diagnostic imaging rule might require an initial lower-intensity intervention for uncomplicated symptoms while exempting red flags. The validity of such a rule depends on the predictive value of red flags, the relative harm of missing serious disease, and the possibility of follow-up. A chemotherapy-support rule might be time-sensitive even when the average case is routine. Clinical assessment therefore involves a distribution of harms and benefits, not simply a binary view of whether a claim is expensive.
Evidence updating has a temporal dimension. New trials can change expected benefit, new adverse-effect reports can change treatment safety, and technologies can change relative cost. Static criteria may drift away from the prevailing clinical literature. A robust institution maintains a versioned criteria register, retrospective exception audit, documented clinical committee decisions, and a mechanism by which treating clinicians can raise contradictory evidence. That governance makes the rule contestable through reasoned clinical evidence rather than through administrative persistence alone.
Expertise, roles, and review independence
A complete process distinguishes an administrative completeness check from substantive clinical review. Administrative personnel can request identifiers and records; clinicians are needed to interpret medical appropriateness. Depending on the procedure, expertise may need to match a specialty or an individual disease. The reviewer must have sufficient time and information to understand why a case falls outside ordinary criteria.
An institutional safeguard is to make the clinical rationale and the reviewer's role visible to later appeal bodies. A peer-to-peer call can be productive if the disagreement is identified, the relevant evidence is available, and the outcome is documented. A call that merely repeats a rule without addressing the patient's case supplies limited clinical review. Audit design should measure whether peer discussion changes outcomes after controlling for documentation and case complexity.
Pharmaceutical necessity as a distinct regime
Drug controls frequently mix formulary status, restrictions on dose, quantity, step therapy, brand substitution, and clinical necessity. The Medicare Part D determinations are a separately regulated class of decisions. The Part D exception process enables clinicians to support a request when a formulary alternative would be ineffective or adverse for an individual. These decisions should not be assigned the non-drug deadlines established by CMS-0057-F merely because both are colloquially called prior authorization.
A medication switch may have consequences for adherence, drug interactions, clinical stability, and monitoring. Drug-specific studies should distinguish first-fill delays from renewals, stable maintenance therapy from new initiation, and clinical deterioration from pharmacy stockouts. Without those distinctions, administrative delays may be falsely credited with events caused by unrelated fulfillment problems. The 2026 prescription-drug cost review documents the diverse administrative cost literature and highlights the risk of collapsing different work settings into one number.
Measuring error in clinical necessity decisions
Clinical appropriateness is not fully observable from an approval code. An outcome can be administratively correct under a written contract but inconsistent with controlling public program rules. It can satisfy the letter of a criterion while being clinically harmful for an unusual patient. It can also be financially costly and nonetheless clinically appropriate. The inspector general case audit found that 13% of the examined already-denied authorization requests met Medicare coverage rules, establishing a documented compliance problem within that sample.
An audit of decision quality needs blinded or appropriately independent review of both approved and adverse cases, with the same clinical evidence time-stamped as it was available to the original reviewer. Cases should be stratified by urgency, service, provider, member characteristics, and criterion version. A sample confined to adverse decisions estimates error conditional on denial, not overall classifier error. The difference is mathematically decisive and should be disclosed in every report claiming an erroneous-denial rate.
Review Delays, Appeals, and Continuity of Care
Regulatory clocks and patient waiting time
The decision clock and the treatment clock measure different processes. A regulatory clock starts when the payer receives a qualifying authorization request under the rules of the program. Clinical waiting time may start when an intervention is recommended, when an order is entered, when symptoms first justify treatment, or when the patient arrives at a referral clinic. The clinician can spend time collecting documentation before transmission, and scheduling can continue after approval. Treating decision turnaround as total wait time misses both intervals.
The CMS-0057-F rule requires many affected payers to decide expedited non-drug prior authorizations within 72 hours and standard non-drug requests within seven calendar days, generally from January 1, 2026, subject to enumerated program details and exceptions. The CMS timing clarification makes clear that clinical urgency may require an even faster response, and that particular statutory programs permit specified extensions. Certain qualified health plan issuers on federally facilitated exchanges are outside this particular shortened-timeframe requirement. These scope distinctions are stated again in the general implementation guidance.
A researcher testing compliance should collect request submission and completion timestamps, urgency category, documentation requests, any permitted extension, the basis for cancellation or withdrawal, and the applicable program regulation. Calendar days must be distinguished from business days. A mean turnaround can hide a dangerous upper tail; median, ninety-fifth percentile, and the proportion of clinically time-critical requests outside the required window should all be examined. A short average does not establish that time-sensitive patients received appropriate care.
The appeal funnel and its selection problem
An initial adverse decision becomes an appeal only when a person or authorized representative contests it through a recognized channel. Reconsiderations, corrected submissions, direct provider conversations, formal internal appeals, and independent external reviews may be recorded under different event identifiers. A study must define which event is counted. The Medicare Part D appeals guidance identifies a five-level appeal sequence for that drug program. Its stages must not be inferred to govern every commercial or public health plan.
KFF's 2024 Medicare Advantage analysis reports that approximately 11.5% of initially denied requests were appealed and 80.7% of those appeals were partly or completely overturned. On the source definitions, the product is 0.115 × 0.807 = 0.092805. Thus about 9.28% of initially adverse decisions were observed to receive a favorable appeal outcome through this measured route. This calculation is conditional: the remaining cases were overwhelmingly not reviewed through the reported appeal process. The 80.7% rate is not an independently audited estimate of the share of all initial decisions that were wrong.
Appeal selection is likely related to the availability of clinician support, health status, language, burden, knowledge of rights, expected benefit, and anticipated success. The consequences are predictable for inference but the sign of selection bias is not predetermined. Well-resourced claimants may appeal strong cases more often; severely ill claimants may also face barriers that disproportionately suppress appeals of meritorious denials. The available administrative denominator cannot decide which mechanism dominates. Research requires details on people who did not appeal, not merely the subset that did.
Notice quality and procedural accessibility
An adverse notice should distinguish the precise coverage criterion from the medical facts relied on, identify the documentation considered, and explain how a clinician or patient may correct or contest the decision. An abstract reason code is difficult to challenge when the relevant rule version is unavailable. Access to interpretation, assistive formats, authorized representatives, and independent decision-makers can alter the practical exercise of appeal rights.
The CMS transparency template requires reporting of categories such as approvals, denials, approvals after appeal, and processing time. Public reporting permits some comparisons, but aggregated numbers do not establish the accuracy of underlying clinical decisions. An individual audit must be able to reconstruct reason codes, clinical record versions, notice delivery, deadlines and the final patient pathway. This is particularly important when a positive result follows supplementation of missing clinical evidence rather than correction of an earlier error of judgment.
Treatment episodes and ongoing authorizations
Some interventions occur once; others consist of a clinically coherent series of services. Requiring new authorization for every visit may add little clinical information after the treatment plan is established and may impose a persistent risk of interruption. Conversely, appropriate re-evaluation can respond to changed medical status or evidence. Review cadence should be compared with the clinical cadence of care and the expected value of new information.
The Medicare Advantage continuity provisions address authorization duration over medically appropriate courses and provide at least 90 days of transition protection for an active course of treatment when moving to a new coordinated-care plan. These safeguards are specific to the regulated program. They illustrate an important analytical principle: a change of insurer can produce a discontinuity in access even when the patient's clinical indication remains constant. A policy audit should distinguish authorization expiration from clinical termination.
Urgent care and the asymmetric cost of delay
A postponed nonurgent elective procedure and a postponed time-sensitive cancer service have different expected consequences. The magnitude of delay and the clinical condition interact. Urgency routing therefore requires a clinically substantiated classification, timely escalation, and an auditable override. A scheme that lowers its expedited fraction may be improving classification or suppressing valid urgent requests; administrative counts alone cannot distinguish the outcomes.
Research should classify requests prospectively by expected deterioration from delay, compare actual time to service, and record the clinical basis for urgent escalation. Emergency stabilization and other immediate clinical duties have separate legal arrangements and should not be assumed to depend on approval. Follow-up measurements should include treatment discontinuation and adverse events, with a causal design capable of distinguishing authorization effects from disease progression and scheduling shortages.
Administrative Burden, Behavioral Responses, and Outcomes
The economic incidence of authorization
Prior authorization requires labor and time from multiple actors. Physicians and staff assemble records, identify criteria, handle electronic or telephone requests, respond to peer review, and file appeals. Insurers and contracted review firms maintain rules, process documentation, employ clinicians, and manage quality control. Patients invest time in calls, transportation, repeated appointments, and uncertainty. Pharmacy staff may handle prescription-specific approval and exception requests. A cost evaluation should measure these functions separately before aggregating to a social perspective.
The 2025 AMA survey reports approximately 40 prior-authorization requests and 13 hours of physician and staff work per week for the respondent physician's practice, alongside perceptions of delays and abandoned treatment. Such survey results indicate sizable reported workload among respondents; they are not a directly validated national employment account and need carefully defined denominators. The stakeholder perceptions study compares 1,005 patients, 1,010 provider employees and 115 payer employees, revealing different vantage points on the same process.
Fixed technological costs should be distinguished from variable request costs. A payer can automate the receipt of structured information while a provider still spends time locating records or mapping clinical indications to a code. A reform that makes a request effortless for an insurer may shift work to providers rather than remove it. An intervention should therefore account for changes in effort among all parties, including the labor spent correcting automated mistakes and obtaining treatment after approval.
The systematic cost review identified fourteen eligible studies of prescription-drug prior authorization costs. Heterogeneous staff categories, settings, and wage assumptions limited direct comparisons. This literature supports methodological caution: a mean cost per request from one pharmacy or physician office should not be multiplied uncritically by national medical procedure counts, since drug and non-drug workflows are operationally distinct.
Anticipatory behavior and the unseen population
Authorization requirements can influence care before a formal request is filed. A physician who expects denial may recommend another therapy, postpone a test, order additional documentation, or avoid submitting a request. Patients may abandon the effort after hearing about paperwork. These are behaviorally significant outcomes that request-level administrative files generally cannot observe. A before-after study of submitted denials may report improvement simply because difficult cases disappear from the submitted-request population.
The provider decision-making study documents self-reported prescribing behavior in a cross-sectional survey, including responses to prior authorization and step-therapy requirements. Its design supports hypotheses about therapeutic substitution but cannot establish an average causal effect on all practices. Electronic orders, prescriber notes, canceled appointments, and patient interviews can complement payer records to trace these omitted pathways.
A change in procedure volume also has ambiguous interpretation. If exemptions lead to more imaging, the additional scans may represent appropriate care that was previously deterred, low-value discretionary use, care delivered sooner rather than later, or substitution away from another intervention. Evaluating the change requires clinical indications, comparable patient risk, and subsequent outcomes. The expenditure effect alone cannot measure clinical welfare.
Clinical studies and the meaning of observed delay
The gynecologic oncology study reviewed 1,406 patients over 2,112 visits at one academic center in 2021, with 83 prior-authorization requests. Among approved requests, the mean time from order placement to service was reported as 16 days, with a 95% interval of 11–20 days. This is the interval observed in those cases, not a demonstrated 16-day delay caused by authorization. Referral, scheduling, facility resources, clinical preparation, and administrative review can all contribute.
The oncology setting illustrates why a causal design must start the clock before decisions and include patients whose care is never completed. Conditioning on approval can selectively exclude the longest and most severely affected pathways. Reporting only the observed mean among completed treatments can create an artificially reassuring picture of the process. Better measures include competing-event cumulative incidence for receipt of clinically recommended care, the frequency of alternative treatment, and clinically meaningful endpoints over a specified follow-up.
Beneficial review and adverse consequences
The expected net benefit of review contains at least two components. A review can avoid unnecessary exposure to ineffective, harmful or redundant interventions, protecting patient safety and shared resources. It can also delay or prevent clinically useful care and impose burden on clinicians, patients and payers. Neither effect follows mechanically from a denial or approval percentage. The validity of the clinical criteria and the path from recommendation to actual treatment determine the outcome.
The OIG sampling investigation identified denied Medicare Advantage requests that met applicable Medicare coverage rules. It thus supports a documented risk of excessive restriction under program-specific circumstances. It does not estimate the entire social balance of authorization or demonstrate that every denial was clinically harmful. A policy evaluation should sample both approved and denied pathways, assess appropriateness independently, and trace downstream clinical and financial outcomes.
Hypothetical accounting of labor and appeals
Consider 10,000 initial requests and apply the 7.7% adverse-decision rate reported in KFF's 2024 MA analysis strictly as an illustrative benchmark. The expected count of initially adverse decisions is 770. If 11.5% of these are appealed, the expected count is 88.55. Multiplication by 80.7% yields 71.45985 expected partly or fully favorable appeal outcomes. Fractional results show the calculation uses expected values, not an invented individual-level database. Neither the favorable appeal count nor the unappealed remainder is an estimate of clinically incorrect original decisions.
Now assume, independently of any source estimate, that 10,000 requests require 25 incremental provider minutes and eight payer minutes each. Provider time totals 250,000 minutes or approximately 4,166.67 hours; payer time totals 80,000 minutes or 1,333.33 hours. Under an assumed policy that removes 30% of the requests without reallocating burden, the arithmetic reduction would be 1,250 provider hours and 400 payer hours. Those are conditional identities, not empirical savings. Changes in service mix, fixed staffing, software maintenance, clinical error, appeals and treatment substitution can reverse the apparent gain.
This illustration demonstrates that an evaluation must specify the perspective: insurer administration, provider staffing, patient opportunity cost, total social cost, or clinical welfare. A payer-only metric can record an efficiency gain while the overall system absorbs more work. Neither an accounting estimate nor a survey alone can establish the optimal level of prospective review.
Data Architecture, Statistics, and Causal Validation
Reconstructing the complete patient pathway
An adequate event dataset should link membership, the ordered intervention, the clinical indication, authorization requirement, documentation versions, submission timestamp, review events, decision, reason, reconsideration, appeal, delivery of the service, and claims payment. Identifiers must distinguish patients from requests and requests from clinical episodes. A new request after an unsuccessful initial determination should carry a relationship to the original episode, preventing inflation of exposed patient counts.
Minimum variables include payer and product, plan year, benefit and service category, severity and urgency, clinical indication, provider and facility, order timestamp, transmission timestamp, acceptance for review, information deficiencies, decision timestamp, type of authorization, reviewer role, criterion version, appeal status, final outcome and delivery timestamp. Missingness and exclusions must be reported. An authorization that remains pending at the end of a database extraction is neither approved nor denied, and treating it as either distorts results.
The CMS contract reporting files provide official aggregate evidence on Medicare Advantage and Part D activities, but may lack patient-level service indication and clinical appropriateness information. The CMS validation procedures specify quality-control issues and potential reporting exclusions. Analysts must retain data-file version, calendar or fiscal year, contract eligibility and changes in reporting specifications, since apparent trends can arise from altered data definitions rather than clinical or administrative change.
Correct denominators and observable rates
The initial adverse-decision rate is initial wholly or partly adverse determinations divided by all qualifying initial determinations. The appeal rate is formally appealed adverse determinations divided by eligible adverse determinations; pending cases require an explicit censoring rule. The appeal reversal rate is partly or fully favorable appeal outcomes divided by appealed determinations reaching a defined adjudication stage. The request-intensity measure is requests per member-year. The episode-based denial rate instead uses unique care episodes with at least one adverse authorization outcome divided by all relevant ordered care episodes.
These measures answer different questions. A person may have more than one request; a denied request may later receive approval through resubmission rather than a formal appeal; and one approved authorization may cover several services. The Medicare Advantage determinations analysis identified roughly 52.8 million determinations in calendar 2024, about 4.1 million fully or partly adverse outcomes, and approximately 1.7 requests per beneficiary. It also discussed far fewer prior-authorization reviews in the traditional Medicare context, which uses a narrower selection of services and a different time basis. A raw cross-program comparison would conflate exposure and regulation.
For uncertainty intervals, a random audit sample can use binomial or clustered sampling methods depending on design; plan reports comprising the full accessible population may have reporting error even without conventional sampling error. Strong results disclose both kinds of uncertainty. A rate quoted to one decimal place should not imply that the underlying input values or inclusion rules are exact.
Distinguishing treatment time from response time
Clinical waiting time may be measured from the physician's order to service delivery, while insurer processing time runs from accepted submission to decision. The observed trajectory can include several events: request prepared, transmitted, returned for missing information, reconsidered, approved, scheduled, canceled or substituted. A meaningful analysis displays duration of each component, including when a member never proceeds to treatment.
Comparing average time among eventually approved patients excludes people whose denial prevents delivery. It can also condition on a future event, generating selection and immortal-time bias. A study should specify a time zero before exposure is resolved, then use time-to-event methods with cancellation, death, alternative treatment and loss of coverage as possible competing events. Delay should be risk-stratified; its clinical consequences are likely service-specific rather than proportional to days uniformly across diseases.
The federal PA metrics reporting framework calls for average and median decision times and appeal-related reporting. Such transparency measures a useful administrative segment but cannot establish total order-to-care time without clinical scheduling records. The observational oncology care-interval analysis is valuable because it supplies order-to-service data, while remaining limited by the absence of an identified counterfactual.
Study designs for policy evaluation
A before-after comparison of an authorization rule risks confounding from enrollment, technology, workforce, disease severity, evolving clinical practice, and payer composition. Difference-in-differences with an appropriately stable comparator, interrupted time series with adequate pre-policy observations, or discontinuity analysis at a defensible eligibility threshold can support stronger inference. Their identifying assumptions must be assessed through pretrends, placebo outcomes, balance of clinical risk, outcome definitions, and credible exposure assignment.
The outcome estimand should be specified before looking at results. Examples include the effect of removing authorization on time from order to completion among clinically indicated orders; the effect on appropriateness-weighted utilization; and the effect on total administrative cost per enrolled member-year. They require different data. An observed increase in service claims may be beneficial, harmful or neutral depending on indications and substitution.
Nonrandom policy adoption can select for payers with atypically high denial rates or providers with unusually well-developed administrative systems. A reform introduced in response to poor performance may display regression to the mean. Difference-in-differences cannot solve bias when the pre-policy trend differs substantially or when comparison plans also change. Negative-control services, sensitivity to service mix, and provider-level stratification can reveal these weaknesses.
Equity and the unsubmitted population
Access to clinical documentation, appeal support, broadband, language interpretation, and clinician time may differ by geography or population. Different denial rates can arise from differing indications, but equal request-level denial rates do not prove equal access if some populations are less likely to obtain an order or to submit a request. A credible equity analysis follows eligible patients from indicated need through actual treatment and compares exposure to review rules, initial submission, appeal propensity and eventual care.
The CMS clinical-individualization guidance is especially relevant when algorithmic processing uses expected length of stay or other aggregate proxies. A subgroup can have acceptable average predictive accuracy and still face unsafe misclassification for rare or complex cases. Monitoring should therefore include clinically significant exception rates and independent review of atypical diagnoses as well as aggregate parity.
Electronic exchange and algorithmic review
Interoperable technology can transfer clinical information and approval status without repeated manual data entry. The CMS interoperability requirements implement specific non-drug prior authorization processes from 2026 and stage relevant payer APIs largely for 2027. The FHIR and X12 technical guidance distinguishes modern clinical-data application programming interfaces from existing administrative transaction frameworks. Technology can reduce lost paperwork and accelerate communication, but a faster transmission does not guarantee clinically sound criteria.
An automated review program should log input data, its completeness, rule and software versions, output and reason, human override, and the ability to reproduce decisions during appeal. Routing straightforward approvals automatically may leave more clinically complex cases for human review. Average processing time can then fall even while the remaining pending cases become more difficult. Appropriate evaluation records both total system burden and clinical outcomes by complexity and urgency.
Data quality, revisions, and replication
A research release should retain a dictionary of event types, source reporting periods, changes in data custodian instructions, definitions of partial approval, and the relationship of appeals to original requests. Aggregate results should be reproducible from defined source tables. The Part C reporting data and CMS retrospective validation must be read together when a dataset reports inconsistent plan coverage or validation flags.
All citations in this monograph connect directly to the named official source, study or precise claim. The accompanying EVIDENCE.json maps each external URL to the proposition it can support and the population to which that proposition applies. These statements do not manufacture independent confirmation of the empirical datasets, and the figures are subject to the limitations of the source's own methods. Regulatory interpretations are fixed to the November 16, 2026 research cutoff and require re-checking if applied after substantive amendments.
International Institutional Comparison
United States: multiple coverage and appeal systems
Medicare Advantage, traditional Medicare, Medicaid fee-for-service, Medicaid managed care, Children's Health Insurance Program coverage, employer plans, marketplace plans, and Part D drug plans differ in covered benefits and legal procedures. Their prior-authorization mechanisms are regulated under different instruments even when insurers or providers use similar software. The Medicare Advantage utilization rule and Part D drug framework must therefore be distinguished at the level of clinical criteria, clocks and appeal rights.
The CMS-0057-F payer scope guidance identifies affected payer types; its operational interpretation notes exceptions to shortened processing limits. The public reporting requirements and APIs also have staged dates. A policy evaluation that labels the 2026 deadlines universal would be legally incorrect. Data should carry a program code, decision type, year and applicability flag for each observation.
The 2026 WISeR model provides a further example of prospective or prepayment review in selected original Medicare services and geographic areas. It is an Innovation Center test distinct from Medicare Advantage. Its design can generate future evaluation opportunities, but launch of a review model is not evidence that clinical outcomes or value improved. Any effect estimate would need the correct comparison population, adoption period and procedures under review.
European Union: reimbursement for cross-border care
The EU cross-border healthcare directive permits authorization requirements for specified categories of cross-border reimbursement within legal limits, including planning needs, hospital care, certain high-cost specialized infrastructure, and safety-related conditions. Member states must apply requirements transparently and within proportionality and nondiscrimination constraints, subject to the detailed provisions of the directive and national implementation.
The legal question is whether advance authorization is justified for cross-border reimbursement under the patient's entitlements and the statutory conditions. It differs from routine preauthorization for an ordinary domestic insurer benefit. A denial of reimbursement for treatment in another member state cannot be combined with a U.S. medical-service denial rate as though the same population, care pathway or decision criterion applied.
An empirical comparison would document national implementing rules, treatment availability in the home system, expected domestic waiting time, payer competence, appeal arrangements and the clinical circumstances justifying travel. Where quantitative comparable data are unavailable, a rigorous result is a documented institutional distinction, rather than an invented cross-country approval rate.
England: exceptional public commissioning
The NHS England funding-request guidance describes how clinicians may seek exceptional funding for specialized treatments not routinely commissioned. The specialized commissioning policy addresses ordinary population-level decisions about service development. These two levels should be differentiated: an individual funding request does not necessarily contest a covered routine benefit, and approval turns on the applicable clinical exceptionality and effectiveness framework.
The distinction is important when interpreting a low approval share. In a tightly defined exceptional process, applications may be deliberately limited to atypical cases outside routine policy. A low approval rate could reflect the boundary of the routine package rather than a high frequency of incorrect decisions about ordinary covered care. Auditors must examine the intended population and applicable criteria before evaluating the fairness of any proportion.
Canada: Ontario drug benefit exceptions
Ontario's Drug Benefit Formulary establishes covered-drug listings, including limited-use conditions and exceptional access pathways for particular drugs. The core scientific object is drug reimbursement for an eligible provincial population rather than a general national medical procedure authorization system. Eligibility, submission, clinical rationale and exception review are matters of Ontario-specific program administration.
Comparative research should distinguish ordinary formulary restriction from a request for exceptional coverage. It should record whether an alternative medication was appropriate, whether an exception was submitted, and whether an authorized drug was subsequently dispensed. No unsupported national authorization rate or Ontario-specific quantitative access effect is asserted here.
Principles of valid comparison
These four jurisdictional examples share a requirement for prospective evidentiary assessment in certain circumstances. Their institutions differ in who funds the service, what is already an entitlement, who requests the exception or approval, and which review and appeal procedures apply. A common comparison can therefore use a structured list of observational questions: what is the benefit, what is the clinical evidence, what institution decides, how long does it take, how can the decision be challenged, and what treatment ultimately occurs?
This observational checklist supports analysis without constructing a purported new scientific doctrine. A legal comparison may be strong where statutory documentation is complete even if outcome data are unavailable. A clinical causal comparison needs indication-level and treatment-level observations, plus an identification design. An economic comparison needs a consistent resource-cost perspective. Separating these claims improves interpretability while permitting an integrated assessment of whether the prospective gate functions coherently within its own system.
Integrated Interpretation and Research Conclusions
Prior authorization is best understood in relation to the care it governs. A payer may accurately issue an approval within a regulatory deadline and still leave a patient waiting because scheduling, referrals or documentation preceded and followed the decision. An insurer may report high approval rates while clinicians avoid submitting difficult requests. An appeal program may reverse most reviewed denials while leaving the majority of initially adverse decisions unappealed. Each statement can be true simultaneously. No single request-level success metric measures the whole process.
A credible medical necessity review system therefore needs clinically valid and updated criteria, documented individualized assessment, proportional burden, properly differentiated standard and expedited clocks, intelligible adverse notices, meaningful appeal rights, and a traceable route from authorization to treatment. This conclusion is a synthesis of the verified legal, administrative and clinical record rather than an independently validated universal design formula.
The 2022 OIG Medicare Advantage audit provides direct evidence that some sampled decisions denied services that met applicable Medicare rules. The 2024 MA administrative summary quantifies request frequency and appeals using different denominators. The physician survey identifies professional experience of time cost; the three-group survey reveals institutional perception differences; and the oncology observational study records treatment intervals and changes within a specified clinical setting. Their joint contribution is stronger when their different sampling frames remain visible.
The scientific priorities follow from these differences. Future studies should link orders, requests, decisions, appeals, actual delivery and clinical outcomes; record unsubmitted orders and abandoned pathways; audit appropriateness in both approved and denied cases; and evaluate regulatory changes under explicit causal designs. They should specify urgency, condition, country or program, costs borne by providers, payers and patients, and whether results are estimates, observations, identities or legal facts.
The principal independent contribution of this dossier is the reconciliation of legal entitlement, clinical necessity, administrative events, and outcome denominators across several institutional regimes. It supplies original analysis of common interpretive errors, transparent mathematical illustrations, and a research-ready measurement specification. No new formal theory is proposed, and no universal causal effect is claimed from data unable to support one.
Technical Appendix: Operational Definitions and Sensitivity Analyses
Minimal fields for a replicable empirical dataset
Record a pseudonymous member identifier; coverage start and end; payer category; plan and calendar year; clinical condition; provider and service; medical recommendation date; required-authorization flag; initial and revised request identifiers; submission channel; time at which the payer accepted a complete request; urgency; material documents; governing criteria version; clinical reviewer role; initial decision and reason; partially approved quantity and duration; further documentation; formal appeal; reversal or affirmation; service delivered, substituted or abandoned; claim status and expenditure; and clinical endpoints within a prespecified horizon.
The data dictionary must declare whether multiple procedure codes form one care episode and how overlapping authorizations are handled. It must distinguish a routine reauthorization from an appeal and from a new clinical episode. Changes in payer eligibility require censoring or linkage rules, and every timestamp needs a time zone. Privacy and lawful data governance should be established before linking medical and insurance files.
Sensitivity tests and arithmetic checks
Recalculate adverse-decision rates with partial approvals counted separately, with corrected submissions collapsed to unique episodes, and with withdrawn requests excluded or treated as a competing status. Test appeals with pending outcomes censored versus included under prespecified bounds. Calculate service delay both from clinical order and from complete payer submission, then stratify by urgency and service group. Examine patterns by plan, provider staffing, disease severity, member characteristics and approval-rule version. The 770, 88.55 and 71.45985 illustrative expected case counts in the main text are derived directly from stated input percentages and are not claims about actual individual cases.
Any audit classification of “incorrect denial” requires an independent clinical and legal reference standard and a sampling frame including the relevant decision categories. A reversal after new evidence is provided is analytically distinct from proof that the original reviewer misapplied the evidence then available. Record both the original and appellate information sets.
Scope and limitations
This manuscript is an international documentary, clinical-methodological and analytical synthesis drawing on selected official regulations, program records, a government audit, surveys, an original clinical observational study, a drug-cost literature review, and comparative government documentation. Its review cutoff is November 16, 2026. It does not constitute a preregistered systematic review of all published studies, a comprehensive audit of every state's or country's changing law, a new patient dataset, a randomized experiment, a causal cross-national model, or external peer review. Quantitative examples are labeled hypothetical, and reported statistics retain their original denominators and study periods.
For subsequent verification, retain the complete source list, links embedded in each scientific chapter, source-to-claim metadata in EVIDENCE.json, manuscript and evidence SHA-256, and the source-control commit. An editor should check new amendments to the cited rules before using the manuscript for contemporary practice beyond its cutoff. Public publication requires a separate release decision and verification of the exact production URL.
Conclusion
Health insurance prior authorization and medical necessity review govern the passage from financial benefit entitlements to actual individual treatment decisions. Their scientific evaluation must integrate the applicable legal rule, patient-specific clinical evidence, institutional review procedure, administrative and clinical timelines, patient access to reconsideration, cumulative resource expenditure, and realized health outcomes. Each level produces distinct indicators; they become meaningful together only when the patient pathway can be reconstructed.
The evidence establishes several durable findings. Medicare Advantage rulemaking requires constrained criteria and individualized assessments in its own regulatory domain. The 2024 CMS-0057-F rule created staged non-drug decision and technical requirements for defined payer classes. A Medicare Advantage government audit identified improper application of coverage criteria among some sampled denials. The 2024 administrative record documents large request volumes and a selected appeal process with frequent reversals. Surveys and specialty clinical studies reveal burdens and observed care pathways while leaving population-level causal effects unresolved. International comparisons establish distinct prospective authorization mechanisms in EU cross-border reimbursement, English NHS exceptional funding, and Ontario drug benefits.
The original analytical result is a rigorous alignment of decision definitions, clinical and regulatory context, statistical denominators, and causal limits. It provides a practical evidence structure for evaluation without claiming a novel doctrine. The governing research conclusion is that the quality of prior authorization is measured by the appropriateness, timeliness, transparency and consequences of the care pathway that follows it, rather than by an isolated insurer decision statistic.
References
Centers for Medicare & Medicaid Services. (2023). 2024 Medicare Advantage and Part D final rule (CMS-4201-F): Fact sheet. https://www.cms.gov/newsroom/fact-sheets/2024-medicare-advantage-and-part-d-final-rule-cms-4201-f
Centers for Medicare & Medicaid Services. (2024, February 6). Frequently asked questions related to coverage criteria and utilization management requirements in CMS final rule CMS-4201-F. HPMS memorandum. https://www.cms.gov/files/document/hpms-memo-faq-coverage-criteria-and-utilization-management-cms-4201-f-02-6-2024-pdf.pdf
Centers for Medicare & Medicaid Services. (2024, January 17). CMS interoperability and prior authorization final rule (CMS-0057-F): Fact sheet. https://www.cms.gov/newsroom/fact-sheets/cms-interoperability-prior-authorization-final-rule-cms-0057-f
Centers for Medicare & Medicaid Services. (n.d., accessed November 16, 2026). Improving prior authorization processes: Frequently asked questions. https://www.cms.gov/initiatives/burden-reduction/overview/interoperability/frequently-asked-questions/improving-prior-authorization-processes
Centers for Medicare & Medicaid Services. (n.d., accessed November 16, 2026). Prior authorization metrics reporting: Overview and template. https://www.cms.gov/prior-authorization-metrics-reporting-overview-template
Centers for Medicare & Medicaid Services. (n.d., accessed November 16, 2026). Parts C and D reporting requirements: Limited data set files. https://www.cms.gov/data-research/cms-data/data-available-researchers/limited-data-set-lds-files/parts-c-d-reporting-requirements-limited-data-set
Centers for Medicare & Medicaid Services. (n.d., accessed November 16, 2026). Part C and Part D data validation. https://www.cms.gov/medicare/coverage/prescription-drug-coverage-contracting/part-c-and-part-d-data-validation
U.S. Department of Health and Human Services, Office of Inspector General. (2022). Some Medicare Advantage organization denials of prior authorization requests raise concerns about beneficiary access to medically necessary care. Report OEI-09-18-00260. https://oig.hhs.gov/reports/all/2022/some-medicare-advantage-organization-denials-of-prior-authorization-requests-raise-concerns-about-beneficiary-access-to-medically-necessary-care/
Biniek, J. F., Sroczynski, N., Freed, M., and Neuman, T. (2026, January 28). Medicare Advantage insurers made nearly 53 million prior authorization determinations in 2024. KFF. https://www.kff.org/medicare/medicare-advantage-insurers-made-nearly-53-million-prior-authorization-determinations-in-2024/
American Medical Association. (2026). 2025 AMA prior authorization physician survey. Chicago: AMA. https://www.ama-assn.org/system/files/prior-authorization-survey.pdf
Sahni, N. R., Istvan, B., Stafford, C., and Cutler, D. (2024). Perceptions of prior authorization burden and solutions. Health Affairs Scholar, 2(9), qxae096. doi:10.1093/haschl/qxae096. https://pmc.ncbi.nlm.nih.gov/articles/PMC11425057/
Salzbrenner, S. G., Lydiatt, M., Helding, B., Scheier, L. M., Greene, H., Hill, P. W., and McAdam-Marx, C. (2023). Influence of prior authorization requirements on provider clinical decision-making. American Journal of Managed Care, 29(7), 331–337. doi:10.37765/ajmc.2023.89394. https://pmc.ncbi.nlm.nih.gov/articles/PMC10403277/
Smith, A. J. B., Mulugeta-Gordon, L., Pena, D., Kanter, G. P., Bekelman, J. E., Haggerty, A. E., and Ko, E. M. (2022). Prior authorization in gynecologic oncology: An analysis of clinical impact. Gynecologic Oncology, 167(3), 519–522. doi:10.1016/j.ygyno.2022.10.002. https://pubmed.ncbi.nlm.nih.gov/36244827/
Carroll, N. V., Carroll, N. W., and Brody, E. R. (2026). Prescription drug prior authorization: Costs to pharmacies and physicians. American Journal of Managed Care, 32(6), 359–364. doi:10.37765/ajmc.2026.89956. https://pubmed.ncbi.nlm.nih.gov/42335264/
Centers for Medicare & Medicaid Services. (n.d., accessed November 16, 2026). Medicare Part D coverage determinations. https://www.cms.gov/medicare/appeals-grievances/prescription-drug/coverage-determinations
Centers for Medicare & Medicaid Services. (n.d., accessed November 16, 2026). Medicare Part D exceptions. https://www.cms.gov/medicare/appeals-grievances/prescription-drug/exceptions
Centers for Medicare & Medicaid Services. (n.d., accessed November 16, 2026). Medicare Part D appeals overview. https://www.cms.gov/medicare/appeals-grievances/prescription-drug/appeals-overview
European Parliament and Council. (2011). Directive 2011/24/EU of 9 March 2011 on the application of patients’ rights in cross-border healthcare. Official Journal of the European Union, L 88, 45–65, notably Articles 7–9. https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=celex%3A32011L0024
NHS England. (2023, reviewed 2026). Individual funding requests for specialised services: A guide for patients. https://www.england.nhs.uk/long-read/individual-funding-requests-for-specialised-services-a-guide-for-patients/
NHS England. (2026). NHS England specialised commissioning service development policy. https://www.england.nhs.uk/long-read/nhs-england-specialised-commissioning-service-development-policy/
Government of Ontario. (n.d., accessed November 16, 2026). Ontario Drug Benefit Formulary and Comparative Drug Index. https://www.formulary.health.gov.on.ca/formulary/searchCriteria.xhtml
Centers for Medicare & Medicaid Services, Innovation Center. (2026). Wasteful and Inappropriate Service Reduction (WISeR) Model. https://www.cms.gov/priorities/innovation/innovation-models/wiser
Centers for Medicare & Medicaid Services. (n.d., accessed November 16, 2026). Application programming interfaces: Relevant standards and implementation guides. https://www.cms.gov/initiatives/burden-reduction/overview/interoperability/implementation-guides-standards/application-programming-interfaces-apis-relevant-standards-implementation-guides-igs
Centers for Medicare & Medicaid Services. (n.d., accessed November 16, 2026). CMS-0057-F general frequently asked questions. https://www.cms.gov/initiatives/burden-reduction/overview/interoperability/frequently-asked-questions/general